| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
865,460 |
| 52
Week Range: |
$191.51 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
39,326 |
485,736 |
| Total Sell Value |
$0 |
$0 |
$8,245,949 |
$88,282,436 |
| Total People Sold |
0 |
0 |
7 |
8 |
| Total Sell Transactions |
0 |
0 |
18 |
71 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Himes Vaughn B |
Chief Technical Officer |
• – – |
2016-12-07 |
4 |
OE |
$9.23 |
$276,900 |
D/D |
30,000 |
165,379 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-12-06 |
4 |
AS |
$65.70 |
$957,145 |
D/D |
(14,465) |
638,835 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-12-06 |
4 |
OE |
$10.20 |
$148,481 |
D/D |
14,465 |
642,877 |
|
- |
|
| Drachman Jonathan G |
CMO & EVP, R & D |
• – – |
2016-11-09 |
4 |
AS |
$66.75 |
$517,379 |
D/D |
(7,751) |
109,837 |
|
- |
|
| Drachman Jonathan G |
CMO & EVP, R & D |
• – – |
2016-11-09 |
4 |
OE |
$11.09 |
$85,959 |
D/D |
7,751 |
117,588 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-11-08 |
4 |
B |
$59.46 |
$19,403,299 |
I/I |
326,300 |
40,885,092 |
2.25 |
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-11-07 |
4 |
AS |
$56.50 |
$845,144 |
D/D |
(14,465) |
638,835 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-11-07 |
4 |
OE |
$10.20 |
$148,481 |
D/D |
14,465 |
642,145 |
|
- |
|
| Lippman Marc E |
Director |
– • – |
2016-11-07 |
4 |
S |
$57.75 |
$57,749 |
D/D |
(1,000) |
131,350 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-11-07 |
4 |
B |
$58.74 |
$3,301,345 |
I/I |
56,200 |
40,590,914 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-11-03 |
4 |
B |
$55.99 |
$11,196,763 |
I/I |
198,433 |
40,540,247 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-11-03 |
4 |
B |
$56.55 |
$21,586,884 |
I/I |
379,336 |
40,361,400 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-11-02 |
4 |
B |
$55.84 |
$26,200,958 |
I/I |
466,619 |
40,019,506 |
2.25 |
- |
|
| Drachman Jonathan G |
CMO & EVP, R & D |
• – – |
2016-11-01 |
4 |
AS |
$51.74 |
$176,847 |
D/D |
(3,418) |
109,837 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-11-01 |
4 |
B |
$51.83 |
$10,057,349 |
I/I |
184,674 |
39,598,943 |
2.25 |
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-10-06 |
4 |
AS |
$54.41 |
$787,022 |
D/D |
(14,465) |
638,835 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-10-06 |
4 |
OE |
$10.20 |
$148,553 |
D/D |
14,465 |
650,058 |
|
- |
|
| Drachman Jonathan G |
CMO & EVP, R & D |
• – – |
2016-09-22 |
4 |
AS |
$56.75 |
$127,631 |
D/D |
(2,249) |
113,255 |
|
- |
|
| Drachman Jonathan G |
CMO & EVP, R & D |
• – – |
2016-09-22 |
4 |
OE |
$10.29 |
$23,142 |
D/D |
2,249 |
115,504 |
|
- |
|
| Dobmeier Eric |
Chief Operating Officer |
• – – |
2016-09-14 |
4 |
S |
$54.03 |
$1,238,470 |
D/D |
(22,918) |
87,767 |
|
- |
|
| Dobmeier Eric |
Chief Operating Officer |
• – – |
2016-09-14 |
4 |
OE |
$12.00 |
$275,016 |
D/D |
22,918 |
88,067 |
|
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-09-13 |
4 |
B |
$50.00 |
$7,213,981 |
I/I |
141,202 |
39,432,496 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2016-09-12 |
4 |
B |
$49.84 |
$2,551,111 |
I/I |
49,889 |
39,305,533 |
2.25 |
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2016-09-10 |
4 |
GD |
$0.00 |
$0 |
I/I |
6,148 |
0 |
|
- |
|
| Cline Darren S |
EVP, Commercial |
• – – |
2016-09-09 |
4 |
OE |
$15.46 |
$64,422 |
D/D |
4,167 |
55,743 |
|
- |
|
1805 Records found
|
|
Page 29 of 73 |
|
|
